EA201891999A1 - КОМПОЗИЦИИ РЕКОМБИНАНТНЫХ ВНУТРИВЕННЫХ ИММУНОГЛОБУЛИНОВ (rIVIG) И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ - Google Patents

КОМПОЗИЦИИ РЕКОМБИНАНТНЫХ ВНУТРИВЕННЫХ ИММУНОГЛОБУЛИНОВ (rIVIG) И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Info

Publication number
EA201891999A1
EA201891999A1 EA201891999A EA201891999A EA201891999A1 EA 201891999 A1 EA201891999 A1 EA 201891999A1 EA 201891999 A EA201891999 A EA 201891999A EA 201891999 A EA201891999 A EA 201891999A EA 201891999 A1 EA201891999 A1 EA 201891999A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rivig
immune
proteins
compositions
transplants
Prior art date
Application number
EA201891999A
Other languages
English (en)
Inventor
Ень-Мин Хсу
Цзэн-Шинь Ли
Хсю-Чин Чан
Original Assignee
Аб Биосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аб Биосайенсиз, Инк. filed Critical Аб Биосайенсиз, Инк.
Publication of EA201891999A1 publication Critical patent/EA201891999A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Abstract

Композиции рекомбинантных внутривенных иммуноглобулиновых (rIVIG) белков и способы очистки и применения белков rIVIG. Указанные композиции содержат олигомерные молекулы Fc, которые связываются с рецепторами Fc с высокой авидностью. Белки rIVIG полезны в качестве иммуномодулирующих молекул для лечения иммунных нарушений, включающих аутоиммунные заболевания, такие как трудно поддающаяся лечению иммунная тромбоцитопения, хроническая воспалительная демиелинизирующая полинейропатия, рассеянный склероз, волчанка, болезнь Грейвса, болезнь Кавасаки, дерматомиозит, миастения гравис, синдром Гийена-Барре, аутоиммунная гемолитическая анемия, и другие иммунные и воспалительные патологии. Указанные белки rIVIG могут также применяться в качестве иммуномодуляторов у пациентов для снижения иммунного отторжения трансплантатов органов, трансплантатов стволовых клеток и трансплантатов костного мозга. Кроме того, данное изобретение предлагает белки rIVIG нечеловеческого происхождения, для применения при ветеринарных иммунных нарушениях, такие как собачьи белки rIVIG для лечения собак, страдающих аутоиммунной гемолитической анемией, иммунной тромбоцитопенической пурпурой, ревматоидным артритом или другим собачьим иммунным нарушением.
EA201891999A 2016-03-30 2017-03-29 КОМПОЗИЦИИ РЕКОМБИНАНТНЫХ ВНУТРИВЕННЫХ ИММУНОГЛОБУЛИНОВ (rIVIG) И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ EA201891999A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662315483P 2016-03-30 2016-03-30
PCT/US2017/024650 WO2017172853A1 (en) 2016-03-30 2017-03-29 Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use

Publications (1)

Publication Number Publication Date
EA201891999A1 true EA201891999A1 (ru) 2019-08-30

Family

ID=59965144

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891999A EA201891999A1 (ru) 2016-03-30 2017-03-29 КОМПОЗИЦИИ РЕКОМБИНАНТНЫХ ВНУТРИВЕННЫХ ИММУНОГЛОБУЛИНОВ (rIVIG) И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Country Status (18)

Country Link
US (2) US11304994B2 (ru)
EP (1) EP3436484A4 (ru)
JP (1) JP7075100B2 (ru)
KR (1) KR102477536B1 (ru)
CN (1) CN109312000A (ru)
AU (1) AU2017245143B2 (ru)
BR (1) BR112018070022A2 (ru)
CA (1) CA3019530A1 (ru)
CL (1) CL2018002769A1 (ru)
CO (1) CO2018011457A2 (ru)
EA (1) EA201891999A1 (ru)
IL (1) IL261968A (ru)
MA (1) MA44517A (ru)
MX (1) MX2018011865A (ru)
SG (1) SG11201808541VA (ru)
TW (1) TWI801336B (ru)
WO (1) WO2017172853A1 (ru)
ZA (1) ZA201806767B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210095006A1 (en) 2017-12-14 2021-04-01 CSL Behring Lengnau AG RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
WO2020077298A1 (en) * 2018-10-11 2020-04-16 Momenta Pharmaceuticals, Inc. Treatment with highly silylated igg compositions
JP2022504868A (ja) * 2018-10-18 2022-01-13 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための、新生仔ｆｃ受容体（ｆｃｒｎ）への結合性が変化したｆｃ変異体
CN109793894A (zh) * 2019-04-03 2019-05-24 长春西诺生物科技有限公司 犬免疫球蛋白在制备犬溶血性贫血药物中的应用
CN114401985A (zh) 2019-09-13 2022-04-26 康诺贝林伦瑙有限公司 用于治疗免疫复合物介导的肾病症的重组IgG Fc多聚体
CN112899301B (zh) * 2021-01-29 2023-04-11 中国热带农业科学院热带生物技术研究所 一种木薯普通花叶病毒诱导的基因沉默系统及其应用
CN115724988B (zh) * 2021-08-26 2023-11-17 瑅安生物医药（杭州）有限公司 一种接近天然分子的多肽融合分子

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8748198A (en) * 1997-08-21 1999-03-16 Takara Shuzo Co., Ltd. Carcinostatic agents
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
EP1395605B8 (en) 2001-03-09 2014-12-17 Iterative Therapeutics, Inc. Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors
US7279329B2 (en) * 2005-10-17 2007-10-09 Industrial Technology Research Institute Expression system for producing collagen
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2008131242A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
NZ581395A (en) 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
CN107011445B (zh) 2007-06-01 2021-06-29 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
CN103154036B (zh) 2010-07-28 2016-05-11 格利克尼克股份有限公司 天然人蛋白片段的融合蛋白以产生有序多聚化免疫球蛋白fc组合物
EP2561888A1 (en) 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
US9962436B2 (en) * 2012-07-26 2018-05-08 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
CA2882296A1 (en) * 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
EP2908914B1 (en) * 2012-10-17 2018-04-18 Liverpool School of Tropical Medicine Immunomodulatory proteins
SI2968461T1 (sl) 2013-03-13 2023-01-31 Genzyme Corporation Fuzijski proteini, ki vsebujejo vezavna dela PDGF in VEGF in postopek njihove uporabe
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
AU2015248785A1 (en) 2014-04-16 2016-11-24 Ucb Biopharma Sprl Multimeric Fc proteins
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof

Also Published As

Publication number Publication date
US11801286B2 (en) 2023-10-31
EP3436484A1 (en) 2019-02-06
JP7075100B2 (ja) 2022-05-25
AU2017245143A1 (en) 2018-10-18
SG11201808541VA (en) 2018-10-30
CO2018011457A2 (es) 2019-02-08
CA3019530A1 (en) 2017-10-05
US20190111115A1 (en) 2019-04-18
MX2018011865A (es) 2019-03-28
KR20180132731A (ko) 2018-12-12
ZA201806767B (en) 2023-04-26
JP2019513024A (ja) 2019-05-23
KR102477536B1 (ko) 2022-12-13
WO2017172853A1 (en) 2017-10-05
IL261968A (en) 2018-10-31
BR112018070022A2 (pt) 2019-02-05
TW201741335A (zh) 2017-12-01
TWI801336B (zh) 2023-05-11
CN109312000A (zh) 2019-02-05
AU2017245143B2 (en) 2024-01-11
CL2018002769A1 (es) 2018-12-28
EP3436484A4 (en) 2019-12-04
US20220233658A1 (en) 2022-07-28
US11304994B2 (en) 2022-04-19
MA44517A (fr) 2019-02-06

Similar Documents

Publication Publication Date Title
EA201891999A1 (ru) КОМПОЗИЦИИ РЕКОМБИНАНТНЫХ ВНУТРИВЕННЫХ ИММУНОГЛОБУЛИНОВ (rIVIG) И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
NZ741404A (en) Anti-il-2 antibodies and compositions and uses thereof
PH12016500242A1 (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
EA201992609A1 (ru) Слитые белки, содержащие интерлейкин-2, и их применения
GEP20207162B (en) Lag-3-binding molecules and methods of use thereof
EA201790342A1 (ru) Антитела к trem2 и способы их применения
EA201690803A1 (ru) Получение переориентирующих т-клетки гетеродимерных иммуноглобулинов
EA201791590A1 (ru) Антитела к tau и их применение
EA201990473A1 (ru) Полиглутамированные антифолаты и их применение
EA201492149A8 (ru) St2-антигенсвязывающие белки
MX2015016111A (es) Anticuerpos anti-b7-h5 y sus usos.
MX2016005765A (es) Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos.
EA201790438A1 (ru) Антигенсвязывающие белки, которые связываются с cxcr5
EA201691521A1 (ru) Антитела к интерлейкину-21
CL2016001028A1 (es) Anticuerpos de alta afinidad y de agregación estable basados en dominios variables de vl y derivados de vhh.
MX2018015265A (es) Metodos para el uso de moleculas de union a cd32b x cd79b en el tratamiento de enfermedades y trastornos inflamatorios.
EA202092302A1 (ru) Антитела к trem-1 и их применения
EA202190807A1 (ru) Антитела к синуклеину
MX371412B (es) ANTICUERPOS BIESPECÍFICOS QUE SE UNEN ESPECÍFICAMENTE A LOXL2 Y ccl.2, COMPOSICIONES DE LOS MISMOS, Y SU USO EN EL TRATAMIENTO DE ESCLERODERMIA.
MX2020007628A (es) Composiciones y metodos de uso.
WO2015187521A3 (en) Anti-blys antibodies
EA201790437A1 (ru) Антигенсвязывающие белки, связывающиеся с cxcr3
GB2543713A (en) Polymeric proteins and uses thereof